Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ASCO 2022
π₯ This #WorldLeukemiaDay watch @zucenka (@VU_LT) discuss data from a study investigating venetoclax combinations in FLT3- and IDH1-mutated acute myeloid #Leukemia:
π π
#Leusm #TrialUpdate #WLD26 #LeukemiaAwareness
Venetoclax combinations show high remission rates in FLT3- and IDH1-mutated AML
Andrius Ε½uΔenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the results of a stu...
ow.ly
As it's #WorldLeukemiaDay, why not listen to our recent podcast episode on the sequencing of BTKi therapy in CLL, which focuses on treatment considerations and emerging strategies.π©Έ
Click here to check it out:
π§ https://ow.ly/8J5y50ZAsJV
#CLLsm #Leusm #Leukemia #HemOnc #WLD26
π¨ The FDA approves ropeginterferon alfa-2b for the treatment of essential thrombocythemia!
This approval introduces the first new FDA-approved treatment for ET in nearly 3 decades, offering a long-acting interferon-based approach supported by durable response and hematologic
Today is #WorldLeukemiaDay β a day to raise awareness, support patients, and highlight the research driving progress in #Leukemia care. ππ©Έ
π₯ Explore our dedicated #Leukemia channel for the latest research, expert insights & breakthroughs:
β‘οΈ
#Leusm
Leukemia | VJHemOnc
Comprehensive leukemia resource covering acute & chronic leukemias, treatments & clinical trials. Expert insights on ALL...
ow.ly
𧬠AAV gene therapy in hemophilia: what comes next?
Hear @RKaczmarekDr discuss the challenges of current AAV-based approaches, including durability, liver toxicity, and potential malignancy risks, alongside emerging non-AAV strategies.
Listen now:
AAV gene therapy in hemophilia: progress, challenges and what comes next | VJHemOnc
This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of adeno-associated virus (AAV)-based...
ow.ly
ASCO 2022
π₯ This #WorldLeukemiaDay watch @zucenka (@VU_LT) discuss data from a study investigating venetoclax combinations in FLT3- and IDH1-mutated acute myeloid #Leukemia:
π π
#Leusm #TrialUpdate #WLD26 #LeukemiaAwareness
Venetoclax combinations show high remission rates in FLT3- and IDH1-mutated AML
Andrius Ε½uΔenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the results of a stu...
ow.ly
As it's #WorldLeukemiaDay, why not listen to our recent podcast episode on the sequencing of BTKi therapy in CLL, which focuses on treatment considerations and emerging strategies.π©Έ
Click here to check it out:
π§ https://ow.ly/8J5y50ZAsJV
#CLLsm #Leusm #Leukemia #HemOnc #WLD26
π¨ The FDA approves ropeginterferon alfa-2b for the treatment of essential thrombocythemia!
This approval introduces the first new FDA-approved treatment for ET in nearly 3 decades, offering a long-acting interferon-based approach supported by durable response and hematologic
Today is #WorldLeukemiaDay β a day to raise awareness, support patients, and highlight the research driving progress in #Leukemia care. ππ©Έ
π₯ Explore our dedicated #Leukemia channel for the latest research, expert insights & breakthroughs:
β‘οΈ
#Leusm
Leukemia | VJHemOnc
Comprehensive leukemia resource covering acute & chronic leukemias, treatments & clinical trials. Expert insights on ALL...
ow.ly
𧬠AAV gene therapy in hemophilia: what comes next?
Hear @RKaczmarekDr discuss the challenges of current AAV-based approaches, including durability, liver toxicity, and potential malignancy risks, alongside emerging non-AAV strategies.
Listen now:
AAV gene therapy in hemophilia: progress, challenges and what comes next | VJHemOnc
This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of adeno-associated virus (AAV)-based...
ow.ly
